High-dose cytarabine monotherapy is superior to standard-dose cytarabine- based multiagent sequential treatment cycle for consolidation treatment in adult (14-59 years) AML patients according to European Leukemia Net 2022 risk stratification

High-dose cytarabine monotherapy is superior to standard-dose cytarabine- based multiagent sequential treatment cycle for consolidation treatment in adult (14-59 years) AML patients according to European Leukemia Net 2022 risk stratification

IntroductionWe firstly investigate based on 2022 European Leukemia Net (ELN) risk stratification, whether standard-dose cytarabine based multiagent sequential chemotherapy (SDMSC) is more beneficial than high-dose cytarabine (HDAC) monotherapy in consolidation for the survival of adult acute myeloid...

Full description

Bibliographic Details
Main Authors: Xiaoyu Wang, Dan Liu, Erling Chen, Li Wang, Na Zhao, Li Zhou, Juan Tong, Lei Xue, Lei Zhang, Liangquan Geng, Baolin Tang, Huilan Liu, Xin Liu, Changcheng Zheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
acute myeloid leukemia
2022 European Leukemia Net
high-dose cytarabine
multiagent sequential chemotherapy
consolidation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1070588/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1070588/full

Similar Items